> Molecular diagnostics company CareDx will pursue an IPO for up to $50 million to fuel the use of next-generation sequencing in new blood tests that monitor heart transplant biomarkers. Story
> Quest Diagnostics ($DGX) said it will offer two of BioMérieux's BRAF mutation companion diagnostics for two of GlaxoSmithKline's ($GSK) melanoma drugs. Story (reg. req.)
> A year after the U.S. Supreme Court ended Myriad Genetics' ($MYGN) legal monopoly on breast-cancer gene testing, efforts to advance more breast cancer gene variants into public databases are accelerating. Story
> A new MRI technique could quicken the diagnosis of traumatic brain injury. Story
> Virtual Radiologic (vRad), a U.S.-based telemedicine and radiology practice, and Ramsay Diagnostics, a network of imaging centers in St. Petersburg and Moscow, will partner to bring U.S. remote radiology imaging services to the Russian market. Release